BROZELIN

This brand name is authorized in Nigeria

Active ingredients

The drug BROZELIN contains a combination of these active pharmaceutical ingredients (APIs):

1 Salbutamol
UNII 021SEF3731 - ALBUTEROL SULFATE

Salbutamol is a selective β2-agonist providing short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction. At therapeutic doses it acts on the β2-adrenoceptors of bronchial muscle. Salbutamol is administered for the symptomatic relief of bronchospasm associated with chronic or acute asthma, bronchitis or other obstructive pulmonary diseases.

Read about Salbutamol
2 Ambroxol
UNII CC995ZMV90 - AMBROXOL HYDROCHLORIDE

Ambroxol induces activation of the surfactant system by acting directly on the type II pneumocytes of the alveoles and the Clara cells in the region of the small airways. It promotes the formation and outward transfer of surface-active material in the alveolar and bronchial region of the foetal and adult lungs.

Read about Ambroxol
3 Guaifenesin
UNII 495W7451VQ - GUAIFENESIN

Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold.

Read about Guaifenesin
4 Menthol
UNII L7T10EIP3A - MENTHOL, UNSPECIFIED FORM
Read about Menthol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R03CK Adrenergics and other drugs for obstructive airway diseases R Respiratory system → R03 Drugs for obstructive airway diseases → R03C Adrenergics for systemic use
Discover more medicines within R03CK

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: NG Registered Drug Product Database Identifier(s): A4-3215

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.